Skip to main content

Tripos Directors Reaffirm Plan to Explore M&A, Divestiture

NEW YORK, May 18 (GenomeWeb News) - Tripos' board of directors have "reaffirmed [their] commitment" to explore options for spurring growth, including selling or merging the firm, going private, or separating its informatics and research businesses.


The comments were made yesterday during the company's annual stockholders' meeting. Also at the meeting, the firm's six directors were re-elected to another one-year term, and the board extended the 1996 Director Stock Compensation Plan.


Tripos has been exploring options for its future since at least January, when the company said it had retained financial advisory firm Seven Hills Partners to identify options to help it grow.


Two months earlier, Tripos announced the end   of its lucrative four-year collaboration with Pfizer.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.